InSightec tests ExAblate therapy in liver and bone cancer trials:
This article was originally published in Clinica
Executive Summary
Israel-based InSightec has initiated two clinical trials in Europe evaluating the benefit of its ExAblate 2000 ablation therapy as a treatment for liver cancer and pain palliation in metastatic bone tumours. Up to 20 patients will be recruited onto each trial, which will be conducted at the Charite Hospital in Berlin, Germany, and St Mary's Hospital in London, UK. ExAblate 2000 uses MRI-guided high-focused ultrasound (MRgFUS) to thermally ablate tissue without the need for surgery. To date, the system, which is compatible with GE Healthcare's Signa MR system, is only approved to treat uterine fibroids.